UPDATE: Morgan Stanley Reiterates Overweight Rating, Removes PT on Pfizer Following Investor Relations Lunch

In a report published Friday, Morgan Stanley analyst David Risinger reiterated an Overweight rating on Pfizer PFE, but removed the $33.00 price target. In the report, Morgan Stanley noted, “We hosted Chuck Triano and Ryan Crowe from Pfizer Investor Relations for lunch in NYC on Thurs. Dec. 12. Discussions focused on Prevnar adult pneumonia prevention trial (CAPiTA), palbociclib breast cancer trial and potential early filing, and business segment reporting and potential breakup. CAPiTA data [is] imminent. The trial has concluded, and Pfizer is analyzing data and will disclose results in a press release in early '14. We assume 80% odds of success because Prevnar has decreased pneumococcal disease since it was introduced. The incremental sales opportunity from a positive CAPiTA could be $2 billion.” Pfizer closed on Thursday at $30.25.